INFLUENCE OF CHRONIC NEUROGENIC PAIN ON LOCAL LEVELS OF SEX HORMONES AND RECEPTORS IN SKIN, TUMOR AND PERIFOCAL AREA IN MALE MICE WITH TRANSPLANTABLE В16/F10 MELANOMA

Local synthesis and metabolism of sex hormones allow the skin to regulate autonomously both nociceptive reactions and proliferative processes in various pathologies.

The purpose of the study was to reveal the influence of chronic neurogenic pain on the balance of sex hormones in the skin, tumor and perifocal area in male mice in the dynamics of В16/F10 melanoma growth.

Material and methods. The study included С57ВL/6 male mice. Animals were divided into the main group – animals with В16/F10 melanoma transplanted after the development of chronic neurogenic pain (n=25), comparison group (n=27) – animals with standard tumor transplantation, controls – males with chronic neurogenic pain (n=8), and intact mice (n=8). Levels of estradiol (E2), estrone (E1), testosterone (T), progesterone (P4) (CUSABIO, China), estrogen receptors – ERα, ERβ (Сloud-Clone Corp. USA, China), progesterone (RP4) and androgens (RA) (CUSABIO, China) were determined in 10 % homogenates of skin, tumor and perifocal tissues 1, 2 and 3 weeks after В16/F10 melanoma transplantation using standard ELISA test systems adapted for experimental animals.

Results. Chronic neurogenic pain causes an imbalance of sex steroids with marked hyperestrogenism. The imbalance is achieved by increased content of estradiol and receptors of estrogen, increased concentration of progesterone with inhibition of its receptor apparatus, as well as reduced levels of testosterone with increased concentration of androgen receptors. Melanoma in animals with chronic neurogenic pain grows and develops in a target organ with an altered steroid balance, which leads to changes in the tumor characteristics. Chronic neurogenic pain and B16/F10 melanoma has a unidirectional effect on the local hormonal status of the skin.

1. Rižner T.L., Thalhammer T., Özvegy-Laczka C. The Importance of Steroid Uptake and Intracrine Action in Endometrial and Ovarian Cancers. Front Pharmacol. 2017 Jun 19; 8: 346. doi: 10.3389/fphar.2017.00346.

2. Konings G., Brentjens L., Delvoux B., Linnanen T., Cornel K., Koskimies P., Bongers M., Kruitwagen R., Xanthoulea S., Romano A. Intracrine Regulation of Estrogen and Other Sex Steroid Levels in Endometrium and Non‑gynecological Tissues; Pathology, Physiology, and Drug Discovery. Front Pharmacol. 2018 Sep 19; 9: 940. doi: 10.3389/fphar.2018.00940.

3. Wang L., Nanayakkara G., Yang Q., Tan H., Drummer C., Sun Y., Shao Y., Fu H., Cueto R., Shan H., Bottiglieri T., Li Y.F., Johnson C., Yang W.Y., Yang F., Xu Y., Xi H., Liu W., Yu J., Choi E.T., Cheng X., Wang H., Yang X. A comprehensive data mining study shows that most nuclear receptors act as newly proposed homeostasis‑associated molecular pattern receptors. J Hematol Oncol. 2017 Oct 24; 10(1): 168. doi: 10.1186/s13045‑017‑0526‑8.

4. Hewitt S.C., Korach K.S. Estrogen receptors: new directions in the new millennium. Endocr Rev. 2018 Oct 1; 39(5): 664–675. doi: 10.1210/er.2018‑00087.

5. Hua H., Zhang H., Kong Q., Jiang Y. Mechanisms for estrogen receptor expression in human cancer. Exp Hematol Oncol. 2018 Sep 19; 7: 24. doi: 10.1186/s40164‑018‑0116‑7.

6. Fox E.M., Davis R.J., Shupnik M.A. ERbeta in breast cancer onlooker, passive player, or active protector? Steroids. 2008 Oct; 73(11): 1039–51. doi: 10.1016/j.steroids.2008.04.006.

7. Lee E., Hsu C., Haiman C.A., Razavi P., Horn-Ross P.L., Van Den Berg D., Bernstein L., Le Marchand L., Henderson B.E., Setiawan V.W., Ursin G. Genetic variation in the progesterone receptor gene and risk of endometrial cancer: a haplotype‑based approach. Carcinogenesis. 2010 Aug; 31(8): 1392–9. doi: 10.1093/carcin/bgq113.

8. Tangen I.L., Werner H.M., Berg A., Halle M.K., Kusonmano K., Trovik J., Hoivik E.A., Mills G.B., Krakstad C., Salvesen H.B. Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions. Eur J Cancer. 2014 Nov; 50(17): 3003–10. doi: 10.1016/j.ejca.2014.09.003.

9. Sinreih M., Hevir N., Rižner T.L. Altered expression of genes involved in progesterone biosynthesis, metabolism and action in endometrial cancer. Chem Biol Interact. 2013 Feb 25; 202(1–3): 210–7. doi: 10.1016/j.cbi.2012.11.012.

10. Gibson D.A., Simitsidellis I., Collins F., Saunders P.T. Evidence of androgen action in endometrial and ovarian cancers. Endocr Relat Cancer. 2014 Aug; 21(4): T203–18. doi: 10.1530/ERC‑13‑0551.

11. Kozlova M.B., Frantziyantz E.M., Vladimirova L.Yu., Anapalyan V.Kh., Bandovkina V.A., Svetitskaya Ya.V., Kuchkina L.P., Bosenko E.S., Logvinenko A.A. Thyroid and glucocorticoid status of patients with benign and malignant pathology of the breast. Siberian Journal of Oncology. 2009; 4: 52–56. (in Russian).

12. Shatova Yu. S., Frantsiyants E.M., Novikova I.A., Vashchenko L.N., Bandovkina V.A., Vereskunova M.I., Khugaeva A.N., Tokmakov V.V. The local hormonal environment of tumor and perifocal zone in patients with breast cancer: data and prospects of their application. Tumors of female reproductive system. 2016; 12(3): 30–35. (in Russian).

13. Kotieva I.M., Kit O.I., Frantsiyants E.M., Bandovkina V.A., Kaplieva I.V., Trepitaki L.K., Cheryarina N.D., Pogorelova Y.A., Blikjan M.V. Effect of chronic pain on the level of sex hormones, prolactin and gonadotropins in serum and pathologically changed skin of female mice in dynamics of malignant melanoma growth. University news. North‑caucasian region. Natural Sciences series. 2018; 198(2): 106–116. (in Russian). doi: 10.23683/0321‑3005.

14. Kit O.I., Frantsiyants E.M., Kotieva I.M., Kaplieva I.V., Trepitaki L.K., Bandovkina V.A., Rozenko L.Ya., Cheryarina N.D., Pogorelova Yu.A. Some mechanisms of increasing malignancy of b16/f10 melanoma in female mice with chronic pain. Russian Journal of Pain. 2017; 53(2): 14–20. (in Russian).

15. Cairns B.E., Gazerani P. Sex‑related differences in pain. Maturitas. 2009 Aug 20; 63(4): 292–6. doi: 10.1016/j.maturitas.2009.06.004.

16. Peng B., Lu B., Leygue E., Murphy L.C. Putative functional characteristics of human estrogen receptor‑beta isoforms. J Mol Endocrinol. 2003; 30: 13–29. doi: 10.1677/jme.0.0300013.

17. Henderson B.E., Feigelson H.S. Hormonal carcinogenesis. Carcinogenesis 2000; 21: 427–433. doi: 10.1093/carcin/21.3.427.

18. Akhmedkhanov A., Zeleniuch-Jacquotte A., Toniolo P. Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives. Ann NY Acad Sci. 2001 Sep; 943: 296–315. doi: 10.1111/j.1749‑6632.2001.tb03811.x.

19. Ikeda K., Horie-Inoue K., Inoue S. Identification of estrogen-responsive genes based on the DNA binding properties of estrogen receptors using high‑throughput sequencing technology. Acta Pharmacol Sin. 2015 Jan; 36(1): 24–31. doi: 10.1038/aps.2014.123.

20. Finlay-Schultz J., Gillen A.E., Brechbuhl H.M., Ivie J.J., Matthews S.B., Jacobsen B.M., Bentley D.L., Kabos P., Sartorius C.A. Breast cancer suppression by progesterone receptors is mediated by their modulation of estrogen receptors and RNA polymerase III. Cancer Res. 2017 Sep 15; 77(18): 4934–4946. doi: 10.1158/0008‑5472.CAN‑16‑3541